Cornerstone Capital Management Holdings’s Alder Biopharmaceuticals ALDR Stock Holding History

Cornerstone Capital Management Holdings’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	$470K	Buy	41,120 +3,500	+9%	+$39.1K	﹤0.01%	1018
2017 Q3	$459K	Buy	37,620 +7,100	+23%	+$74K	﹤0.01%	1065
2017 Q2	$349K	Buy	30,520 +3,616	+13%	+$66.9K	﹤0.01%	1079
2017 Q1	$559K	Buy	+26,904	New	+$596K	﹤0.01%	1039
2016 Q4	–	Sell	-5,662	Closed	-$185K	–	1466
2016 Q3	$185K	Buy	5,662 +2,662	+89%	+$81.1K	﹤0.01%	1201
2016 Q2	$74K	Buy	+3,000	New	+$81.2K	﹤0.01%	1292
2015 Q4	–	Sell	-5,400	Closed	-$176K	–	1573
2015 Q3	$176K	Sell	5,400 -3,100	-36%	-$132K	﹤0.01%	1243
2015 Q2	$450K	Buy	+8,500	New	+$309K	﹤0.01%	1034

Other funds holding ALDR

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Cornerstone Capital Management Holdings's ALDR Position: Q4 2017 in Review

Cornerstone Capital Management Holdings increased its Alder Biopharmaceuticals (ALDR) stake by 9.3% in Q4 2017, buying an estimated $39.1K and bringing the position to 41,120 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #1018.

Cornerstone Capital Management Holdings first reported a position in ALDR in Q2 2015 and has held it in 8 quarters since. The position peaked at $559K in Q1 2017. 140 funds tracked by Wall St. Rank hold ALDR as of Q4 2017.

Cornerstone Capital Management Holdings held 41,120 shares of Alder Biopharmaceuticals worth $470K as of Q4 2017.
Cornerstone Capital Management Holdings bought 3,500 Alder Biopharmaceuticals shares in Q4 2017, an estimated $39.1K.
Alder Biopharmaceuticals made up ﹤0.01% of Cornerstone Capital Management Holdings's portfolio in Q4 2017, its #1018 holding.
Cornerstone Capital Management Holdings first reported a position in Alder Biopharmaceuticals in Q2 2015 and has held it in 8 quarters since.
Cornerstone Capital Management Holdings's Alder Biopharmaceuticals position peaked at $559K in Q1 2017.
140 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2017.

Based on Cornerstone Capital Management Holdings's 13F filing for Q4 2017, filed 14 Feb 2018.